Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

BPaL(M) Regimen for the Treatment of MDR/RR-TB — Stella

Home/Multidrug- and Rifampicin-resistant Tuberculosis/BPaL(M) Regimen for the Treatment of MDR/RR-TB

View on ClinicalTrials.gov

Recruiting

Back to Multidrug- and Rifampicin-resistant Tuberculosis trials

BPaL(M) Regimen for the Treatment of MDR/RR-TB

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

South Korea

Asan Medical Center, Seoul, Songpa-gu

Key details

Phase

Post-approval study

Sponsor

Asan Medical Center

Collaborators

Pusan National University Hospital, Samsung Medical Center

Enrollment target

~80 participants

Started

December 2022

Primary completion

December 2027

Age range

19 Years and older

Last updated March 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.